Eli Lilly’s 7.5, 12.5 and 15 milligram solutions of Mounjaro are in short supply, and the drugmaker predicts supply levels to normalize by the end of July, the FDA said in a July 25 post. The 10 milligram solution is also on back order, and that shortage is expected to end in September.
The company listed the reason for the shortage as “demand increase.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
